Product Information
PITAVASTATIN 4 MG TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $1.0291 per EA under NDC 65862081490. Its NADAC has been published 137 times since Feb 21, 2024.
FDA first approved this application on Dec 20, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
4 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862081490
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PITAVASTATIN CALCIUMApproval Type
Generic (ANDA)
FDA Application
ANDA206015FDA Approved
12/20/2016
TE Code
AB
On Market Since
11/2/2023
Pharmacological Classes
Price Statistics
The NADAC for PITAVASTATIN 4 MG TABLET has been published 137 times since Feb 21, 2024, and over the history we have for it it has declined 56.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0291 per EA |
|---|---|
| All-time high | $2.3451 (Mar 13, 2024) |
| All-time low | $1.0291 (Sep 23, 2026) |
| 52-week high | $1.5488 |
| 52-week low | $1.0291 |
| Median price | $1.5488 |
| Average price | $1.5945 |
| Largest weekly change | +24.9% (Aug 21, 2024) |
| Weeks tracked | 137 |
| Tracking since | Feb 21, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Pitavastatin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
HMG-CoA Reductase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PITAVASTATIN 4 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PITAVASTATIN 4 MG TABLET, manufactured by Aurobindo Pharma Limited, is $1.0291 per EA (NDC 65862081490), effective Sep 30, 2026.
How has the price of PITAVASTATIN 4 MG TABLET changed over time?
Over the history we have for it, the NADAC for PITAVASTATIN 4 MG TABLET has declined 56.1%. It has been tracked across 137 weekly CMS publications since Feb 21, 2024.
What are the highest and lowest recorded NADAC prices for PITAVASTATIN 4 MG TABLET?
Since Feb 21, 2024, the NADAC for PITAVASTATIN 4 MG TABLET has ranged from a low of $1.0291 (Sep 23, 2026) to a high of $2.3451 (Mar 13, 2024), with a median of $1.5488 per EA.
Are there cheaper alternatives to PITAVASTATIN 4 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as PITAVASTATIN 4 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures PITAVASTATIN 4 MG TABLET?
PITAVASTATIN 4 MG TABLET (NDC 65862081490) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.